Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18902833 | 0.83 | MAOA (0.36) | MAOAMAOBSIGMAR1ARPLK1 | |
| SCHEMBL19754081 | 0.76 | SIGMAR1 (0.42) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL17929118 | 0.76 | HTR2A (0.45) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL17811537 | 0.76 | SIGMAR1 (0.46) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL12869906 | 0.75 | MAOA (0.47) | MAOAMAOBSLC2A1PLK1 | |
| SCHEMBL81907 | 0.75 | SIGMAR1 (0.64) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL17811539 | 0.75 | SIGMAR1 (0.49) | SIGMAR1HTR2AHRH1 | |
| SCHEMBL4740370 | 0.73 | SIGMAR1 (0.62) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL8100113 | 0.73 | SIGMAR1 (0.62) | SIGMAR1HTR2AHRH1CYP19A1 | |
| SCHEMBL10578613 | 0.73 | SIGMAR1 (0.62) | SIGMAR1HTR2AHRH1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | TRINSEO EUROPE GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | ELOVL5, ELOVL3, ELOVL1 | MAOA 1229/4885MAOB 2182/4885SIGMAR1 2592/4885 |
| US-20160159956-A1 | Polymerisation Initiators | ELOVL5, ELOVL3, ELOVL1 | MAOA 1229/4885MAOB 2182/4885SIGMAR1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.